Engineering of bacterial strains and their products for cancer therapy
The use of live bacteria in cancer therapies offers exciting possibilities. Nowadays, an increasing number of genetically engineered bacteria are emerging in the field, with applications both in therapy and diagnosis. In parallel, purified bacterial products are also gaining relevance as new classes...
Gespeichert in:
| Veröffentlicht in: | Applied microbiology and biotechnology 2013-06, Vol.97 (12), p.5189-5199 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 5199 |
|---|---|
| container_issue | 12 |
| container_start_page | 5189 |
| container_title | Applied microbiology and biotechnology |
| container_volume | 97 |
| creator | Bernardes, Nuno Chakrabarty, Ananda M. Fialho, Arsenio M. |
| description | The use of live bacteria in cancer therapies offers exciting possibilities. Nowadays, an increasing number of genetically engineered bacteria are emerging in the field, with applications both in therapy and diagnosis. In parallel, purified bacterial products are also gaining relevance as new classes of bioactive products to treat and prevent cancer growth and metastasis. In the first part of the article, we review the latest findings regarding the use of live bacteria and products as anti-cancer agents, paying special attention to immunotoxins, proteins, and peptides. In particular, we focus on the recent results of using azurin or its derived peptide as anticancer therapeutic agents. In the second part, we discuss the challenges of using metagenomic techniques as a distinctive approach for discovering new anti-cancer agents from bacterial origin. |
| doi_str_mv | 10.1007/s00253-013-4926-6 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_1372059945</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A340943417</galeid><sourcerecordid>A340943417</sourcerecordid><originalsourceid>FETCH-LOGICAL-c586t-77f0ed68e0c220f3c9a28fec8ef6ac27ff53e264b92d0d44f13b77aa935f19c43</originalsourceid><addsrcrecordid>eNp1kV9rFDEUxYModq1-AF9kwBd9mPbm_-SxlFYLhYLV55DN3Kwps5k1mYH225thq3TFkoeQm9853MMh5D2FEwqgTwsAk7wFylthmGrVC7KigrMWFBUvyQqolq2Wpjsib0q5A6CsU-o1OWJcCaFFtyKXF2kTE2KOadOMoVk7P9WHG5oyZRdTaVzqm-knxtzs8tjPfipNGHPjXfKYl5_sdg9vyavghoLvHu9j8uPy4vv51_b65svV-dl162WnplbrANirDsEzBoF741gX0HcYlPNMhyA5MiXWhvXQCxEoX2vtnOEyUOMFPyaf9r51l18zlsluY_E4DC7hOBdLuWYgjRGyoh__Qe_GOae6XaWk7LSk5gm1cQPamMJYY_vF1J5xAUZwQXWlTv5D1dPjNvoxYYh1fiD4fCCozIT308bNpdir22-HLN2zPo-lZAx2l-PW5QdLwS49233PtvZsl56tqpoPj-Hm9Rb7v4o_xVaA7YGyW6rF_CT9s66_AeEjr6Q</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1355875195</pqid></control><display><type>article</type><title>Engineering of bacterial strains and their products for cancer therapy</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>Bernardes, Nuno ; Chakrabarty, Ananda M. ; Fialho, Arsenio M.</creator><creatorcontrib>Bernardes, Nuno ; Chakrabarty, Ananda M. ; Fialho, Arsenio M.</creatorcontrib><description>The use of live bacteria in cancer therapies offers exciting possibilities. Nowadays, an increasing number of genetically engineered bacteria are emerging in the field, with applications both in therapy and diagnosis. In parallel, purified bacterial products are also gaining relevance as new classes of bioactive products to treat and prevent cancer growth and metastasis. In the first part of the article, we review the latest findings regarding the use of live bacteria and products as anti-cancer agents, paying special attention to immunotoxins, proteins, and peptides. In particular, we focus on the recent results of using azurin or its derived peptide as anticancer therapeutic agents. In the second part, we discuss the challenges of using metagenomic techniques as a distinctive approach for discovering new anti-cancer agents from bacterial origin.</description><identifier>ISSN: 0175-7598</identifier><identifier>EISSN: 1432-0614</identifier><identifier>DOI: 10.1007/s00253-013-4926-6</identifier><identifier>PMID: 23644748</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer-Verlag</publisher><subject>Analysis ; Antibody-toxin conjugates ; Antimitotic agents ; Antineoplastic agents ; Antineoplastic Agents - isolation & purification ; Antineoplastic Agents - metabolism ; Antineoplastic Agents - therapeutic use ; Apoptosis ; Azurin - metabolism ; Bacteria ; Bacteria - genetics ; Bacteria - metabolism ; Bacterial Proteins - metabolism ; Bacterial Toxins - metabolism ; Biological Therapy - methods ; Biomedical and Life Sciences ; Biotechnology ; Biotechnology - methods ; Cancer ; Cancer therapies ; Care and treatment ; Cell death ; Clinical medicine ; Clinical trials ; Computational Biology ; Cytotoxicity ; Gene therapy ; Genes ; Genetic engineering ; Genetically modified organisms ; Genomics ; Gram-positive bacteria ; Health aspects ; Immune system ; Immunotherapy ; Immunotoxins ; Immunotoxins - metabolism ; Life Sciences ; Metabolic Engineering - methods ; Metabolic Networks and Pathways - genetics ; Metagenomics ; Microbial Genetics and Genomics ; Microbiology ; Mini-Review ; Neoplasms - diagnosis ; Neoplasms - therapy ; Peptides ; Prevention ; Proteins ; Salmonella ; Studies ; Technology, Pharmaceutical - methods ; Tumors</subject><ispartof>Applied microbiology and biotechnology, 2013-06, Vol.97 (12), p.5189-5199</ispartof><rights>Springer-Verlag Berlin Heidelberg 2013</rights><rights>COPYRIGHT 2013 Springer</rights><rights>Springer-Verlag 2013</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c586t-77f0ed68e0c220f3c9a28fec8ef6ac27ff53e264b92d0d44f13b77aa935f19c43</citedby><cites>FETCH-LOGICAL-c586t-77f0ed68e0c220f3c9a28fec8ef6ac27ff53e264b92d0d44f13b77aa935f19c43</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00253-013-4926-6$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00253-013-4926-6$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,780,784,27924,27925,41488,42557,51319</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23644748$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Bernardes, Nuno</creatorcontrib><creatorcontrib>Chakrabarty, Ananda M.</creatorcontrib><creatorcontrib>Fialho, Arsenio M.</creatorcontrib><title>Engineering of bacterial strains and their products for cancer therapy</title><title>Applied microbiology and biotechnology</title><addtitle>Appl Microbiol Biotechnol</addtitle><addtitle>Appl Microbiol Biotechnol</addtitle><description>The use of live bacteria in cancer therapies offers exciting possibilities. Nowadays, an increasing number of genetically engineered bacteria are emerging in the field, with applications both in therapy and diagnosis. In parallel, purified bacterial products are also gaining relevance as new classes of bioactive products to treat and prevent cancer growth and metastasis. In the first part of the article, we review the latest findings regarding the use of live bacteria and products as anti-cancer agents, paying special attention to immunotoxins, proteins, and peptides. In particular, we focus on the recent results of using azurin or its derived peptide as anticancer therapeutic agents. In the second part, we discuss the challenges of using metagenomic techniques as a distinctive approach for discovering new anti-cancer agents from bacterial origin.</description><subject>Analysis</subject><subject>Antibody-toxin conjugates</subject><subject>Antimitotic agents</subject><subject>Antineoplastic agents</subject><subject>Antineoplastic Agents - isolation & purification</subject><subject>Antineoplastic Agents - metabolism</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>Apoptosis</subject><subject>Azurin - metabolism</subject><subject>Bacteria</subject><subject>Bacteria - genetics</subject><subject>Bacteria - metabolism</subject><subject>Bacterial Proteins - metabolism</subject><subject>Bacterial Toxins - metabolism</subject><subject>Biological Therapy - methods</subject><subject>Biomedical and Life Sciences</subject><subject>Biotechnology</subject><subject>Biotechnology - methods</subject><subject>Cancer</subject><subject>Cancer therapies</subject><subject>Care and treatment</subject><subject>Cell death</subject><subject>Clinical medicine</subject><subject>Clinical trials</subject><subject>Computational Biology</subject><subject>Cytotoxicity</subject><subject>Gene therapy</subject><subject>Genes</subject><subject>Genetic engineering</subject><subject>Genetically modified organisms</subject><subject>Genomics</subject><subject>Gram-positive bacteria</subject><subject>Health aspects</subject><subject>Immune system</subject><subject>Immunotherapy</subject><subject>Immunotoxins</subject><subject>Immunotoxins - metabolism</subject><subject>Life Sciences</subject><subject>Metabolic Engineering - methods</subject><subject>Metabolic Networks and Pathways - genetics</subject><subject>Metagenomics</subject><subject>Microbial Genetics and Genomics</subject><subject>Microbiology</subject><subject>Mini-Review</subject><subject>Neoplasms - diagnosis</subject><subject>Neoplasms - therapy</subject><subject>Peptides</subject><subject>Prevention</subject><subject>Proteins</subject><subject>Salmonella</subject><subject>Studies</subject><subject>Technology, Pharmaceutical - methods</subject><subject>Tumors</subject><issn>0175-7598</issn><issn>1432-0614</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNp1kV9rFDEUxYModq1-AF9kwBd9mPbm_-SxlFYLhYLV55DN3Kwps5k1mYH225thq3TFkoeQm9853MMh5D2FEwqgTwsAk7wFylthmGrVC7KigrMWFBUvyQqolq2Wpjsib0q5A6CsU-o1OWJcCaFFtyKXF2kTE2KOadOMoVk7P9WHG5oyZRdTaVzqm-knxtzs8tjPfipNGHPjXfKYl5_sdg9vyavghoLvHu9j8uPy4vv51_b65svV-dl162WnplbrANirDsEzBoF741gX0HcYlPNMhyA5MiXWhvXQCxEoX2vtnOEyUOMFPyaf9r51l18zlsluY_E4DC7hOBdLuWYgjRGyoh__Qe_GOae6XaWk7LSk5gm1cQPamMJYY_vF1J5xAUZwQXWlTv5D1dPjNvoxYYh1fiD4fCCozIT308bNpdir22-HLN2zPo-lZAx2l-PW5QdLwS49233PtvZsl56tqpoPj-Hm9Rb7v4o_xVaA7YGyW6rF_CT9s66_AeEjr6Q</recordid><startdate>20130601</startdate><enddate>20130601</enddate><creator>Bernardes, Nuno</creator><creator>Chakrabarty, Ananda M.</creator><creator>Fialho, Arsenio M.</creator><general>Springer-Verlag</general><general>Springer</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>ISR</scope><scope>3V.</scope><scope>7QL</scope><scope>7T7</scope><scope>7WY</scope><scope>7WZ</scope><scope>7X7</scope><scope>7XB</scope><scope>87Z</scope><scope>88A</scope><scope>88E</scope><scope>88I</scope><scope>8AO</scope><scope>8FD</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8FL</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BEZIV</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FRNLG</scope><scope>FYUFA</scope><scope>F~G</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K60</scope><scope>K6~</scope><scope>K9.</scope><scope>L.-</scope><scope>LK8</scope><scope>M0C</scope><scope>M0S</scope><scope>M1P</scope><scope>M2P</scope><scope>M7N</scope><scope>M7P</scope><scope>P64</scope><scope>PQBIZ</scope><scope>PQBZA</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7QO</scope></search><sort><creationdate>20130601</creationdate><title>Engineering of bacterial strains and their products for cancer therapy</title><author>Bernardes, Nuno ; Chakrabarty, Ananda M. ; Fialho, Arsenio M.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c586t-77f0ed68e0c220f3c9a28fec8ef6ac27ff53e264b92d0d44f13b77aa935f19c43</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Analysis</topic><topic>Antibody-toxin conjugates</topic><topic>Antimitotic agents</topic><topic>Antineoplastic agents</topic><topic>Antineoplastic Agents - isolation & purification</topic><topic>Antineoplastic Agents - metabolism</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>Apoptosis</topic><topic>Azurin - metabolism</topic><topic>Bacteria</topic><topic>Bacteria - genetics</topic><topic>Bacteria - metabolism</topic><topic>Bacterial Proteins - metabolism</topic><topic>Bacterial Toxins - metabolism</topic><topic>Biological Therapy - methods</topic><topic>Biomedical and Life Sciences</topic><topic>Biotechnology</topic><topic>Biotechnology - methods</topic><topic>Cancer</topic><topic>Cancer therapies</topic><topic>Care and treatment</topic><topic>Cell death</topic><topic>Clinical medicine</topic><topic>Clinical trials</topic><topic>Computational Biology</topic><topic>Cytotoxicity</topic><topic>Gene therapy</topic><topic>Genes</topic><topic>Genetic engineering</topic><topic>Genetically modified organisms</topic><topic>Genomics</topic><topic>Gram-positive bacteria</topic><topic>Health aspects</topic><topic>Immune system</topic><topic>Immunotherapy</topic><topic>Immunotoxins</topic><topic>Immunotoxins - metabolism</topic><topic>Life Sciences</topic><topic>Metabolic Engineering - methods</topic><topic>Metabolic Networks and Pathways - genetics</topic><topic>Metagenomics</topic><topic>Microbial Genetics and Genomics</topic><topic>Microbiology</topic><topic>Mini-Review</topic><topic>Neoplasms - diagnosis</topic><topic>Neoplasms - therapy</topic><topic>Peptides</topic><topic>Prevention</topic><topic>Proteins</topic><topic>Salmonella</topic><topic>Studies</topic><topic>Technology, Pharmaceutical - methods</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Bernardes, Nuno</creatorcontrib><creatorcontrib>Chakrabarty, Ananda M.</creatorcontrib><creatorcontrib>Fialho, Arsenio M.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Gale In Context: Science</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Access via ABI/INFORM (ProQuest)</collection><collection>ABI/INFORM Global (PDF only)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ABI/INFORM Global (Alumni Edition)</collection><collection>Biology Database (Alumni Edition)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ABI/INFORM Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Business Premium Collection</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Business Premium Collection (Alumni)</collection><collection>Health Research Premium Collection</collection><collection>ABI/INFORM Global (Corporate)</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Business Collection (Alumni Edition)</collection><collection>ProQuest Business Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ABI/INFORM Professional Advanced</collection><collection>ProQuest Biological Science Collection</collection><collection>ABI/INFORM Global</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Science Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Business</collection><collection>ProQuest One Business (Alumni)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>Biotechnology Research Abstracts</collection><jtitle>Applied microbiology and biotechnology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bernardes, Nuno</au><au>Chakrabarty, Ananda M.</au><au>Fialho, Arsenio M.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Engineering of bacterial strains and their products for cancer therapy</atitle><jtitle>Applied microbiology and biotechnology</jtitle><stitle>Appl Microbiol Biotechnol</stitle><addtitle>Appl Microbiol Biotechnol</addtitle><date>2013-06-01</date><risdate>2013</risdate><volume>97</volume><issue>12</issue><spage>5189</spage><epage>5199</epage><pages>5189-5199</pages><issn>0175-7598</issn><eissn>1432-0614</eissn><abstract>The use of live bacteria in cancer therapies offers exciting possibilities. Nowadays, an increasing number of genetically engineered bacteria are emerging in the field, with applications both in therapy and diagnosis. In parallel, purified bacterial products are also gaining relevance as new classes of bioactive products to treat and prevent cancer growth and metastasis. In the first part of the article, we review the latest findings regarding the use of live bacteria and products as anti-cancer agents, paying special attention to immunotoxins, proteins, and peptides. In particular, we focus on the recent results of using azurin or its derived peptide as anticancer therapeutic agents. In the second part, we discuss the challenges of using metagenomic techniques as a distinctive approach for discovering new anti-cancer agents from bacterial origin.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer-Verlag</pub><pmid>23644748</pmid><doi>10.1007/s00253-013-4926-6</doi><tpages>11</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0175-7598 |
| ispartof | Applied microbiology and biotechnology, 2013-06, Vol.97 (12), p.5189-5199 |
| issn | 0175-7598 1432-0614 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1372059945 |
| source | MEDLINE; SpringerLink Journals - AutoHoldings |
| subjects | Analysis Antibody-toxin conjugates Antimitotic agents Antineoplastic agents Antineoplastic Agents - isolation & purification Antineoplastic Agents - metabolism Antineoplastic Agents - therapeutic use Apoptosis Azurin - metabolism Bacteria Bacteria - genetics Bacteria - metabolism Bacterial Proteins - metabolism Bacterial Toxins - metabolism Biological Therapy - methods Biomedical and Life Sciences Biotechnology Biotechnology - methods Cancer Cancer therapies Care and treatment Cell death Clinical medicine Clinical trials Computational Biology Cytotoxicity Gene therapy Genes Genetic engineering Genetically modified organisms Genomics Gram-positive bacteria Health aspects Immune system Immunotherapy Immunotoxins Immunotoxins - metabolism Life Sciences Metabolic Engineering - methods Metabolic Networks and Pathways - genetics Metagenomics Microbial Genetics and Genomics Microbiology Mini-Review Neoplasms - diagnosis Neoplasms - therapy Peptides Prevention Proteins Salmonella Studies Technology, Pharmaceutical - methods Tumors |
| title | Engineering of bacterial strains and their products for cancer therapy |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-26T02%3A26%3A14IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Engineering%20of%20bacterial%20strains%20and%20their%20products%20for%20cancer%20therapy&rft.jtitle=Applied%20microbiology%20and%20biotechnology&rft.au=Bernardes,%20Nuno&rft.date=2013-06-01&rft.volume=97&rft.issue=12&rft.spage=5189&rft.epage=5199&rft.pages=5189-5199&rft.issn=0175-7598&rft.eissn=1432-0614&rft_id=info:doi/10.1007/s00253-013-4926-6&rft_dat=%3Cgale_proqu%3EA340943417%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1355875195&rft_id=info:pmid/23644748&rft_galeid=A340943417&rfr_iscdi=true |